Perez-Tirse J, Gross P A
Department of Internal Medicine, Hackensack Medical Center, New Jersey.
Pharmacoeconomics. 1992 Sep;2(3):198-206. doi: 10.2165/00019053-199202030-00003.
Vaccination is an underutilised, low cost and effective method of preventing illness. Cost-effectiveness analysis discloses a beneficial role of influenza vaccination in preventing illness especially in patients over 65 years of age and in high risk patients. In one large study, when 150 million doses of influenza vaccine were given between 1971 and 1977 in the US, over 13 million more years of life were gained at a cost of only $US63 per year of life gained (1978 dollars). The vaccination programmes also resulted in productivity gains of approximately 5 million days which was valued at $US250 million. Other studies from Canada, Finland and the US found similar benefits. The findings of these studies are reviewed. In order to increase the use of influenza immunisation substantially, there has to be a greater acceptance of the value of immunisation by healthcare providers and the public.
接种疫苗是一种未得到充分利用、低成本且有效的预防疾病的方法。成本效益分析揭示了流感疫苗接种在预防疾病方面的有益作用，尤其是在65岁以上的患者和高危患者中。在一项大型研究中，1971年至1977年期间美国接种了1.5亿剂流感疫苗，多获得了超过1300万年的生命，每获得一年生命的成本仅为63美元（1978年美元）。疫苗接种计划还带来了约500万个工作日的生产力提升，价值2.5亿美元。加拿大、芬兰和美国的其他研究也发现了类似的益处。对这些研究的结果进行了综述。为了大幅增加流感疫苗的接种率，医疗服务提供者和公众必须更认可疫苗接种的价值。
